Showing results (301-310 of 378) with videos related to

Sort By:
Pageof 38
European Urology|August 27, 2019
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate CancerAlex P Hoyle, Adnan Ali, Nicholas D James, et al.
Genetic Epidemiology|June 4, 2009
Prostate cancer segregation analyses using 4390 families from UK and Australian population-based studiesRobert J MacInnis, Antonis C Antoniou, Rosalind A Eeles, et al.
The Lancet. Oncology|December 16, 2011
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trialDavid Dearnaley, Isabel Syndikus, Georges Sumo, et al.
BMJ Open|January 1, 2021
Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidanceShaista Hafeez, Amanda Webster, Vibeke N Hansen, et al.
BMC Cancer|October 8, 2016
DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancerImran Petkar, Keith Rooney, Justin W G Roe, et al.
JNCI Cancer Spectrum|October 3, 2023
Radium-223 in metastatic castration-resistant prostate cancer: whole-body diffusion-weighted magnetic resonance imaging scanning to assess responseChris Parker, Nina Tunariu, Holly Tovey, et al.
European Urology Oncology|September 7, 2021
Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016)John N Staffurth, Joanne S Haviland, Anna Wilkins, et al.
Cancer Treatment Reviews|May 9, 2021
Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensusBarbara A Jereczek-Fossa, Giulia Marvaso, Mattia Zaffaroni, et al.
Genetic Epidemiology|July 20, 2011
A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impactRobert J Macinnis, Antonis C Antoniou, Rosalind A Eeles, et al.
Radiology|November 23, 2016
Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot StudyRaquel Perez-Lopez, Joaquin Mateo, Helen Mossop, et al.
Pageof 38